Amylyx Pharmaceuticals (AMLX) Research & Development (2021 - 2026)

Amylyx Pharmaceuticals has reported Research & Development for 6 years, with the latest figure at $23.8 million in Q2 2026.

• On a quarterly basis, Research & Development fell 12.67% year-over-year to $23.8 million in Q2 2026; TTM through Jun 2026 was $92.4 million, a 1.09% decrease from a year earlier, with the FY2025 full-year figure at $90.4 million, down 13.14% from the prior year.
• Research & Development was $23.8 million for Q2 2026 at Amylyx Pharmaceuticals, down from $27.6 million in the prior quarter.
• The five-year high for Research & Development was $44.9 million in Q4 2023, with the low at $19.9 million in Q3 2025.
• Average Research & Development over 5 years is $26.0 million, with a median of $24.0 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Research & Development soared 212.7% in 2022, then tumbled 49.03% in 2024.
• Over 5 years, Research & Development stood at $22.8 million in 2022, then jumped by 96.88% to $44.9 million in 2023, then plunged by 49.03% to $22.9 million in 2024, then slipped by 7.33% to $21.2 million in 2025, then climbed by 12.04% to $23.8 million in 2026.
• The last three Research & Development figures came in at $23.8 million (Q2 2026), $27.6 million (Q1 2026), and $21.2 million (Q4 2025), per Business Quant data.